Use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2

a technology of glucocorticoid receptor and ii antagonist, which is applied in the field of glucocorticoid receptor antagonists, can solve the problems of depression-like state, confusion, asthenia, myalgia, etc., and achieve the effect of milding the symptoms of depression

Inactive Publication Date: 2010-07-15
CORCEPT THERAPEUTICS INC
View PDF2 Cites 26 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0018]The invention provides a method of ameliorating the symptoms of depression in a patient taking IL-2 and having normal cortisol levels and not suffering from clinical depression, as diagnosed by a professional, at the time IL-2 therapy is commenced. The method co

Problems solved by technology

Each of the cytokines commonly used for medical treatment, however, is reported to produce side-effects such as asthenia, myalgia, confusion, and influenza-like symptoms.
In addition, immunotherapy with IL-2 or IFN-α may result in a depression-like state that may be attenuated by treatment with an antidepressant.
In addition, the study, which did not contain a control group against which the results could be

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2

Examples

Experimental program
Comparison scheme
Effect test

example 1

Use of Mifepristone to Ameliorate Symptoms of Depression in a Patient Undergoing IL-2 Therapy

[0127]The following example demonstrates how to practice the methods of the invention.

Patient Selection

[0128]Individuals who are to begin or are currently undergoing IL-2 therapy. The patient typically has normal levels of cortisol for his or her age.

Dosage Regimen and Administration of Mifepristone

[0129]The glucocorticoid receptor (GR) antagonist, mifepristone, is used in this study. It is administered in dosages of 200 mg daily. Individuals will be given 200 mg of mifepristone daily for six months and evaluated as described below. Dosages will be adjusted if necessary and further evaluations will be performed periodically throughout treatment.

[0130]Mifepristone tablets are available from commercial sources such as Shanghai Hua Lian Pharmaceuticals Co., Ltd., Shanghai, China.

Assessing Amelioration of Symptoms of Depression

[0131]To delineate and assess the effectiveness of mifepristone in am...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Dimensionless propertyaaaaaaaaaa
Dimensionless propertyaaaaaaaaaa
Dimensionless propertyaaaaaaaaaa
Login to view more

Abstract

The invention pertains to the discovery that type II glucocorticoid receptor antagonists can be used in methods for reversing or inhibiting the symptoms of depression in patients receiving interleukin-2 treatment.

Description

CROSS-REFERENCES TO RELATED APPLICATIONS[0001]This application claims benefit of U.S. Provisional Application No. 60 / 797,265, filed May 2, 2006, which is herein incorporated by reference in its entirety.FIELD OF INVENTION[0002]This invention relates to the use of glucocorticoid receptor antagonists as a method for ameliorating the symptoms of depression in a patient taking interleukin-2 (IL-2).BACKGROUND OF THE INVENTION[0003]Cytokines are small protein molecules that are actively secreted by immune cells and other cell types. Cytokines function to orchestrate immune system responses and coordinate those responses with other physiological systems in the body. Their action is often local, but can effect the whole body, including the nervous system. Common examples of cytokines include interferon-α (IFNα), IFNβ, IFNγ, interleukin-1 (IL-1), IL-2, IL-6, IL-10, granulocyte macrophage-colony stimulating factor (GM-CSF), and tumor necrosis factor-α (TNF-α).[0004]Cytokines have been shown t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/57A61K31/58A61K31/44A61K31/4164A61K31/4439A61K31/47A61K31/496A61K31/5375A61K31/5377
CPCG06F12/0246
Inventor BELANOFF, JOSEPH
Owner CORCEPT THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap